Correvio Pharma Corp. (CORV) Analysts See $-0.22 EPS

July 14, 2018 - By Frank Plummer

Analysts expect Correvio Pharma Corp. (NASDAQ:CORV) to report $-0.22 EPS on August, 14.They anticipate $0.04 EPS change or 15.38 % from last quarter’s $-0.26 EPS. After having $-0.24 EPS previously, Correvio Pharma Corp.’s analysts see -8.33 % EPS growth. The stock decreased 0.26% or $0.01 during the last trading session, reaching $3.91. About 36,471 shares traded. Correvio Pharma Corp. (NASDAQ:CORV) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. The company has market cap of $136.71 million. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. It currently has negative earnings. The company's portfolio of marketed brands include Xydalba for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.

More news for Correvio Pharma Corp. (NASDAQ:CORV) were recently published by: Investingnews.com, which released: “Pharmaceutical Update: Q2 2018 in Review” on July 10, 2018. Streetinsider.com‘s article titled: “Correvio Pharma (CORV) Reports At The Market Offering” and published on July 10, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.